Inhibrx Biosciences, Inc. INBX
Updated: 17 Jun 2026
No signal published yet
We already track Inhibrx Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Inhibrx Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Inhibrx Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 15, 2026, the company announced that the U.S. FDA accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) for the treatment of conventional chondrosarcoma. The FDA set a PDUFA goal date of April 14, 2027, for the potential approval of the therapy.
What Firelda Watch includes for Inhibrx Biosciences, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Inhibrx Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Inhibrx Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more